BioSpace News Archive

-Safety switches can be applied to CAR T, stem cell, and TCR Therapies - -Cells are created using a gene knockout, maintaining stability of the cells, avoiding additional genetic material and immunogenicity - -Manufacturing process enables 100% population of cells with a safety switch -

Hemogenyx Pharmaceuticals plc (LSE:HEMO)(“Hemogenyx Pharmaceuticals” or the “Company”), announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company (“Share Options”) to certain PDMRs and a member of the Scientific Advisory Board of the Company

BioMatrix Specialty Pharmacy announced today preferred network status for AscellaHealth’s bleeding disorder patient population. The decision to include BioMatrix in the PBM’s national network was based

In lieu of an in-person update to the media, Dr. Howard Njoo, Canada’s Deputy Public Health Officer, issued the following statement on behalf of Dr. Theresa Tam, Canada’s Chief Public Health Officer.

uLab Systems, the creator of uDesign - the treatment planning software designed for orthodontists - is expanding its product offering to include aligner manufacturing

Transparency Life Sciences (TLS) today announced the addition of Craig Lipset to the advisory board.

InductiveHealth Informatics (InductiveHealth), a public health technology firm known for bringing innovation to the public health informatics industry and currently playing a critical role in the COVID-19 public health response, welcomes Alexis Sulyma to the team as chief growth officer to drive the firm’s continued expansion.

Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.

Professor Cheng Chao-Min of the Institute of Biomedical Engineering at National Tsing Hua University has recently developed a new covid-19 rapid test kit which allows the physician to provide timely treatment to high-risk patients, thereby making more efficient use of such critical equipment as respirators.